港股開盤 | 三大指數低開,恆科跌0.8%
【三大指數】
恆生指數開盤跌40.45點,跌幅0.14%,報28417.99點;
國企指數開盤跌53.46點,跌幅0.50%,報10649.11點;
恆生科技指數開盤跌64.08點,跌幅0.80%,報7961.23點。
【異動板塊】
物業股、醫美概念股、航運股走強;
鋼鐵股走弱,科技股承壓,網易跌超3%。
【異動個股】
被新納入恆生指數的3支股票中,信義光能漲超4%,比亞迪股份、碧桂園服務均漲超2%;
康希諾生物漲超1%,獲新冠疫苗獲匈牙利頒發GMP認證;
康方生物漲超3%,與中國生物製藥開發的抗PD-1單抗藥物“派安普利”已經向美國食品藥品監督管理局啓動提交生物製品許可申請用於三線治療轉移性鼻咽癌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.